Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | APP | P05067 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25338631 | 0.86 | NPC1 (0.46) | ALDH1A1MAPTHTTMAOBAPP | |
| SCHEMBL29172279 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPTHTTMAOBAPP | |
| SCHEMBL25947183 | 0.80 | MAOB (0.50) | ALDH1A1MAPTHTTMAOBAPP | |
| SCHEMBL25335458 | 0.79 | ALDH1A1 (0.49) | ALDH1A1MAPTHTTMAOBAPP | |
| SCHEMBL29172297 | 0.78 | NPC1 (0.49) | ALDH1A1MAPTHTTMAOBAPP | |
| SCHEMBL17185931 | 0.73 | APP (0.54) | MAOBAPPNPC1RAB9APOLB | |
| SCHEMBL15487329 | 0.72 | NPC1 (0.57) | MAOBAPPNPC1RAB9APOLB | |
| SCHEMBL18418720 | 0.72 | APP (0.53) | MAOBAPPNPC1RAB9APOLB | |
| SCHEMBL25597570 | 0.71 | APP (0.64) | ALDH1A1MAPTHTTMAOBAPP | |
| SCHEMBL25947185 | 0.71 | MAOB (0.57) | ALDH1A1MAPTHTTMAOBAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | ALDH1A1 4346/4885MAPT 663/4885HTT 3845/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | ALDH1A1 2196/4885MAPT 119/4885HTT 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.